XTX Topco Ltd Acquires New Holdings in Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN)

XTX Topco Ltd acquired a new stake in shares of Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 9,045 shares of the company's stock, valued at approximately $307,000.

Other large investors also recently made changes to their positions in the company. GAMMA Investing LLC boosted its position in shares of Legend Biotech by 145.4% during the 1st quarter. GAMMA Investing LLC now owns 1,291 shares of the company's stock valued at $44,000 after purchasing an additional 765 shares in the last quarter. GF Fund Management CO. LTD. bought a new position in shares of Legend Biotech during the 4th quarter valued at about $56,000. Shell Asset Management Co. boosted its position in shares of Legend Biotech by 62.0% during the 4th quarter. Shell Asset Management Co. now owns 2,090 shares of the company's stock valued at $68,000 after purchasing an additional 800 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in shares of Legend Biotech by 355.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 4,480 shares of the company's stock valued at $146,000 after purchasing an additional 3,496 shares in the last quarter. Finally, Bayesian Capital Management LP bought a new position in shares of Legend Biotech during the 4th quarter valued at about $247,000. Institutional investors own 70.89% of the company's stock.

Analysts Set New Price Targets

LEGN has been the subject of several recent analyst reports. Morgan Stanley raised their target price on shares of Legend Biotech from $81.00 to $83.00 and gave the stock an "overweight" rating in a report on Tuesday. Royal Bank Of Canada reiterated an "outperform" rating and issued a $77.00 target price (up from $75.00) on shares of Legend Biotech in a report on Tuesday. Truist Financial decreased their target price on shares of Legend Biotech from $88.00 to $71.00 and set a "buy" rating for the company in a report on Wednesday, May 14th. Johnson Rice reiterated a "buy" rating on shares of Legend Biotech in a report on Thursday, July 17th. Finally, UBS Group set a $54.00 target price on shares of Legend Biotech and gave the stock a "buy" rating in a report on Wednesday, July 2nd. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, Legend Biotech currently has a consensus rating of "Buy" and an average price target of $72.38.

Legend Biotech Stock Down 0.1%

Shares of LEGN stock traded down $0.05 during trading on Friday, hitting $37.66. 239,303 shares of the company were exchanged, compared to its average volume of 1,477,437. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.07 and a current ratio of 4.71. The firm has a market capitalization of $6.92 billion, a price-to-earnings ratio of -42.75 and a beta of 0.26. The business's 50-day simple moving average is $37.81 and its 200 day simple moving average is $35.18. Legend Biotech Corporation Sponsored ADR has a twelve month low of $27.34 and a twelve month high of $59.62.

Legend Biotech (NASDAQ:LEGN - Get Free Report) last posted its quarterly earnings results on Monday, August 11th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.12). The company had revenue of $255.06 million for the quarter, compared to analyst estimates of $237.49 million. Legend Biotech had a negative return on equity of 32.00% and a negative net margin of 40.83%. The business's revenue for the quarter was up 36.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.05) earnings per share. As a group, analysts forecast that Legend Biotech Corporation Sponsored ADR will post -1.31 EPS for the current fiscal year.

Legend Biotech Profile

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).